Brought to you by 
Amgen, Xencor partner to create XmAb-generated compounds for cancer and inflammation
27 Oct 2021
Executive Summary
Concurrent with announcing its acquisition of Dezima Pharma BV for $300mm in cash up front plus up to $1.25bn in earn-outs, Amgen Inc. is teaming up with Xencor Inc. to develop and commercialize six therapeutics aimed at immuno-oncology and inflammation by applying Xencor's XmAb bispecific technology platform to molecules aimed at human protein targets chosen by Amgen.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amgen, Xencor partner to create XmAb-generated compounds for cancer and inflammation
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice